Bassil Dahiyat Sells 114,377 Shares of Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil Dahiyat sold 114,377 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the completion of the sale, the chief executive officer owned 466,635 shares of the company’s stock, valued at approximately $7,330,835.85. This represents a 19.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Xencor Stock Down 1.5%

Shares of NASDAQ XNCR opened at $15.22 on Friday. The company has a market capitalization of $1.09 billion, a PE ratio of -8.60 and a beta of 0.96. The stock’s 50 day moving average price is $15.51 and its 200-day moving average price is $11.44. Xencor, Inc. has a twelve month low of $6.92 and a twelve month high of $24.88.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.64. Xencor had a negative return on equity of 20.44% and a negative net margin of 87.14%.The business had revenue of $21.00 million for the quarter, compared to analyst estimates of $29.73 million. During the same period last year, the company posted ($0.71) earnings per share. Xencor’s quarterly revenue was up 18.0% compared to the same quarter last year. As a group, research analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on XNCR. Bank of America lowered shares of Xencor from a “buy” rating to a “neutral” rating and reduced their price target for the company from $23.00 to $12.00 in a research report on Wednesday, September 3rd. JPMorgan Chase & Co. reduced their target price on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Truist Financial began coverage on shares of Xencor in a research note on Monday, November 24th. They set a “buy” rating and a $29.00 price target for the company. Barclays upped their price objective on Xencor from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Finally, Cantor Fitzgerald boosted their target price on Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.88.

Hedge Funds Weigh In On Xencor

Large investors have recently made changes to their positions in the stock. State of Wyoming purchased a new position in shares of Xencor in the first quarter valued at $34,000. Hantz Financial Services Inc. grew its holdings in Xencor by 209.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 2,156 shares in the last quarter. GAMMA Investing LLC grew its holdings in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Xencor during the third quarter valued at about $44,000. Finally, Federated Hermes Inc. lifted its holdings in shares of Xencor by 114.3% in the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 2,105 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.